Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: SIX Swiss Ex
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Large Pharma

NOVN:VX

98.500 CHF 1.500 1.55%

As of 11:43:59 ET on 05/27/2015.

Snapshot for Novartis AG (NOVN)

Open: 96.900 Day's Range: 96.900 - 98.600 Volume: 4,211,443
Previous Close: 97.000 52wk Range: 76.050 - 102.700 1-Yr Rtn: +25.24%

Stock Chart for NOVN

No chart data available.
  • NOVN:VX 98.550
  • 1D
  • 1M
  • 1Y
97.000
Interactive NOVN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for NOVN

Current P/E Ratio (ttm) 23.8117
Estimated P/E(12/2015) 19.7783
Relative P/E vs. SMI 1.1963
Earnings Per Share (USD) (ttm) 4.3600
Est. EPS (USD) (12/2015) 5.2390
Est. PEG Ratio 3.0536
Market Cap (M CHF) 263,683.81
Shares Outstanding (M) 2,676.99
30 Day Average Volume 4,101,367
Price/Book (mrq) 3.2915
Price/Sale (ttm) 4.8741
Dividend Indicated Gross Yield 2.64%
Cash Dividend (CHF) 2.6000
Dividend Ex-Date 03/03/2015
5 Year Dividend Growth 4.36%
Next Earnings Announcement 07/21/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for NOVN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for NOVN

Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company produces pharmaceuticals for cardiovascular, respiratory and infectious diseases, oncology, neuroscience, transplantation, dermatology, gastrointestinal and urinary conditions, and arthritis, vaccines and diagnostics, vision, and animal health products.

Joseph Jimenez Jr "Joe"Chief Executive OfficerHarry KirschChief Financial Officer
Andre Wyss "Andy"President:SwitzerlandMark C FishmanPresident:Nibr
More Company Profile & Key Executives for NOVN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil